The emergence of next-generation sequencing (NGS) and extensive collaboration with the cancer community have made possible a new understanding of the genes and pathways that drive tumor growth. These advances help propel targeted pharmaceutical development and bring us closer to the realization of precision medicine. As a leader in NGS technology, Illumina is investing in the development of novel clinical oncology solutions. Join our Medical Affairs leadership team to learn about the basic principles of next-generation sequencing. Explore the applications of genomics in oncology for germline risk prediction and precision medicine, including how NGS demonstrates the importance of circulating nucleic acids for molecular monitoring.